Immune checkpoint inhibitors plus VEGF tyrosine kinase inhibitors as second-line or later therapy for patients with extensive stage small cell lung cancer

被引：0

作者：

Yan, N. ^{[1
]}

Guo, S. X. ^{[1
]}

Li, M. J. ^{[1
]}

Huang, S. Y. ^{[1
]}

Guo, Q. Q. ^{[1
]}

Geng, D. ^{[1
]}

Zhang, H. X. ^{[1
]}

Li, X. ^{[2
]}

机构：

[1] Zhengzhou Sch Med, Affiliate Hosp 1, Oncol Dept, Zhengzhou, Peoples R China

[2] Zhengzhou Univ, Affiliated Hosp 1, Med Oncol, Zhengzhou, Peoples R China

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.243

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1659P

引用

页码：S1168 / S1168

页数：1

共 50 条

[31] Combination therapy using low-dose anlotinib and immune checkpoint inhibitors for extensive-stage small cell lung cancer
Li, Han
Yuan, Shumin
Wu, Han
Wang, Yajie
Ma, Yichen
Tang, Xiance
Fu, Xiaomin
Zhao, Lingdi
Xu, Benling
Li, Tiepeng
Qin, Peng
You, Hongqin
Han, Lu
Wang, Zibing
CANCER INNOVATION, 2024, 3 (06):
[32] Tyrosine kinase inhibitors plus immune checkpoint inhibitors as neoadjuvant therapy for hepatocellular carcinoma: an emerging option?
Rizzo, Alessandro
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2022, 31 (04) : 333 - 335
[33] Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
Rittberg, Rebekah
Leung, Bonnie
Al-Hashami, Zamzam
Ho, Cheryl
FRONTIERS IN ONCOLOGY, 2022, 12
[34] Association Between the Type of First-Line Chemotherapy and Outcome of Second-Line Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Kim, M.
Roh, J.
Eom, J. S.
Lee, M. K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S342 - S342
[35] First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients
Salazar, Fernanda
Angel Molina, Miguel
Sanchez-Ronco, Maria
Moran, Teresa
Luis Ramirez, Jose
Miguel Sanchez, Jose
Stahel, Rolf
Garrido, Pilar
Cobo, Manuel
Isla, Dolores
Bertran-Alamilloh, Jordi
Massuti, Bartomeu
Cardenal, Felipe
Manegold, Christian
Lianes, Pilar
Manuel Trig, Jose
Javier Sanchez, Jose
Taron, Miquel
Rosell, Rafael
LUNG CANCER, 2011, 72 (01) : 84 - 91
[36] CNS efficacy of immune checkpoint inhibitors when combined to stereotactic radiosurgery in extensive stage small cell lung cancer
Awidi, M.
Perimbeti, S.
Wang, C.
Attwood, K.
Jain, P.
ANNALS OF ONCOLOGY, 2023, 34 : S1070 - S1070
[37] Real World Eligibility of Immune Checkpoint Inhibitors with Platinum-Doublet in Extensive Stage Small Cell Lung Cancer
Rittberg, R.
Leung, B.
Al-Hashami, Z.
Ho, C.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S550 - S551
[38] Real-World Utilization of Immune Checkpoint Inhibitors in Extensive Stage Small Cell Lung Cancer in Community Settings
Zu, K.
Arunachalam, A.
Hohlbauch, A.
Silver, M.
Annavarapu, S.
Pietanza, M. C.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1185 - S1185
[39] Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Uenami, T.
Mori, M.
Shiroyama, T.
Nagatomo, I.
Ihara, S.
Komuta, K.
Suzuki, H.
Hirashima, T.
Kimura, M.
Imamura, F.
ANNALS OF ONCOLOGY, 2019, 30
[40] Immune Checkpoint Inhibitors and Chemoradiation for Limited-Stage Small Cell Lung Cancer
Brian Schlick
Misty Dawn Shields
Julian A. Marin-Acevedo
Ishika Patel
Bruna Pellini
Current Treatment Options in Oncology, 2022, 23 : 1104 - 1120

← 1 2 3 4 5 →